Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | AMY1A | P0DUB6 | 7/20 | 0.47 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.42 |
| ▸ | CFB | P00751 | 3/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | FABP6 | P51161 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21102087 | 0.88 | KDM4E (0.57) | KDM4ELMNAHSD17B10AMY1AAAK1 | |
| SCHEMBL24313050 | 0.84 | KDM4E (0.53) | KDM4ELMNAHSD17B10AMY1AAAK1 | |
| SCHEMBL12724845 | 0.83 | KDM4E (0.62) | KDM4ELMNAHSD17B10AMY1ACYP1A2 | |
| SCHEMBL17702668 | 0.80 | AMY1A (0.51) | KDM4EAMY1APDE3BPDE3AFABP6 | |
| SCHEMBL7473230 | 0.77 | KDM4E (0.46) | KDM4ELMNAHSD17B10AMY1AAAK1 | |
| SCHEMBL5990707 | 0.77 | KDM4E (0.56) | KDM4ELMNAHSD17B10AMY1AAAK1 | |
| SCHEMBL17300677 | 0.77 | HSD17B10 (0.56) | KDM4ELMNAHSD17B10AMY1ACYP1A2 | |
| SCHEMBL16599647 | 0.77 | KDM4E (0.56) | KDM4ELMNAHSD17B10AMY1ACYP1A2 | |
| SCHEMBL13542756 | 0.77 | KDM4E (0.56) | KDM4ELMNAHSD17B10AMY1APDE3B | |
| SCHEMBL12938095 | 0.77 | KDM4E (0.69) | KDM4ELMNAHSD17B10AAK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220096441-A1 | TREATMENT OF ACANTHAMOEBA OR BALAMUTHIA TROPHOZOITES AND/OR CYSTS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220096441-A1 | TREATMENT OF ACANTHAMOEBA OR BALAMUTHIA TROPHOZOITES AND/OR CYSTS | PKD2, PKD1, MUC1 | KDM4E 3891/4885LMNA 3130/4885HSD17B10 2450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.